Activation of inflammation and coagulation after infusion of C-reactive protein in humans

Circulation Research

Volumn 96, Issue 7, 2005, Pages 714-716

  Bisoendial, Radjesh J ^a   Kastelein, John J P ^a   Levels, Johannes H M ^a   Zwaginga, Jaap J ^a   Van Den Bogaard, Bas ^a   Reitsma, Pieter H ^a   Meijers, Joost C M ^a   Hartman, Daniel ^b   Levi, Marcel ^a   Stroes, Erik S G ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b PFIZER INC   (United States)

Author keywords

Atherosclerosis; Endothelium; Inflammation; Thrombosis

Indexed keywords

C REACTIVE PROTEIN; RECOMBINANT HUMAN C REACTIVE PROTEIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CONTROLLED STUDY; HUMAN; HUMAN EXPERIMENT; INFLAMMATION; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; THROMBOGENESIS; THROMBOSIS; VOLUNTEER;

ADULT; ARTERIOSCLEROSIS; BLOOD COAGULATION; C-REACTIVE PROTEIN; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; INFLAMMATION; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECOMBINANT PROTEINS;

EID: 20244363246     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.0000163015.67711.AB     Document Type: Article

References (10)

1. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy Am women. Circulation. 2003;107:391-397.
2. Liuzzo O, Biasucci LM, Gallimore JR, Grille RL, Rebuzzi AG, Pepys MB, Maseri A. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med. 1994;331:417-424.
3. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557-1565.
4. Verma S, Wang CH, Li SH, Dumont AS, Fedak PW, Badiwala MV, Dhillon B, Weisel RD, Li RK, Mickle DA, Stewart DJ. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation. 2002;106:913-919.
5. Venugopal SK, Devaraj S, Yuhanna I, Shaul P, Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation. 2002;106:1439-1441.
6. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000;102:2165-2168.
7. Danenberg HD, Szalai AJ, Swaminathan RV, Peng L, Chen Z, Seifert P, Fay WP, Simon DI, Edelman ER. Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice. Circulation. 2003; 108: 512-515.
8. Paul A, Ko KW, Li L, Yechoor V, McCrory MA, Szalai AJ, Chan L. C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2004;109:647-655.
9. Levi M, Ten Cate H, Bauer KA, van der PT, Edgington TS, Buller HR, Van Deventer SJ, Hack CE, ten Cate JW, Rosenberg RD. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest. 1994;93:114-120.
10. Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood. 1993;82:513-520.